Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rSIFN-co in Advanced Solid Tumors
NCT02387307Phase 1Completed
- Sponsor
- Sichuan Huiyang Life Engineering
- Start
- Jul 2013
- Primary completion
- Jun 2018
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of recombinant super-compound interferon in solid tumor, non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC) and 3 more, sponsored by Sichuan Huiyang Life Engineering. Primary endpoints: Adverse Events of rSIFN-co and Recommended Dose at Cycle 1. Started Jul 2013; status: completed.
02
Drugs
recombinant super-compound interferon
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)renal cell carcinoma (RCC)melanomahepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT02387307.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02387307.